| Description |
Diagnosis classification and risk stratification are of crucial in the survival prognostication and treatment selection of acute myeloid leukemia (AML). Here, we used a database of 536 AML patients to compare the 4th and 5th WHO, as well as the 2017 and 2022 version of ELN guidance. Also, we constructed a risk model for Chinese AML patients. The biggest change observed in the 5th WHO classification was the AML-NOS subgroup (n=212), in detail, 8 patients of which were divided into the AML with KMT2A-rearrangement, 25 patients were divided into the AML-MR , and 1 case was divided into the AML with NUP98-rearrangement subgroup. Referring to the ELN guidance, 16 patients in the favorable group,6 patients in adverse group and 13 patients in the intermediate group based on the 2017 ELN guidance were re-classified to intermediate and adverse group based on the 2022 ELN guidance. Regrettably, the Kaplan-Meier curves showed that the survival of intermediate and adverse group could not be distinguished well according to either the 2017 and 2022 ELN guidance. Based on this, we established a risk model for Chinese AML patients and our model could divided the patients into favorable, intermediate and adverse groups well. |
